A randomized, double-blind, placebo-controlled trial published in Nature Medicine tested dronabinol (synthetic THC oil) for trauma-related nightmares. Over 10 weeks, more than a third of treated participants reported their nightmares disappeared; overall nightmare severity fell more in the drug group than placebo.
In a 10-week, four-center randomized trial of 171 adults with PTSD and frequent severe nightmares, dronabinol cut nightmare burden more than placebo and eliminated nightmares completely for over one-third of treated participants.
The study used careful blinding (placebo matched for look, taste, smell) and a titrated dose schedule (2.5 to 15 mg daily, once nightly) to reduce unblinding and side effects.
Investigators propose a biological rationale: THC’s action on the endocannabinoid system may dampen REM-sleep processes involved in replaying traumatic memories, rather than solely sedating patients.
# What the trial tested Researchers at Charité–Universitätsmedizin Berlin and three other German university centers ran a randomized, double-blind, placebo-controlled trial to see whether dronabinol — a pharmaceutical form of THC delivered as oil drops — could reduce trauma-related nightmares in people with PTSD. The results were published in Nature Medicine in August 2026.
# Who took part and how the trial worked The trial enrolled 171 adults with PTSD and frequent severe nightmares across four centers: Charité–Universitätsmedizin Berlin, the Psychiatric University Clinic of the Charité at St. Hedwig Hospital, University Medical Center Hamburg-Eppendorf, and the Central Institute for Mental Health in Mannheim.
# Main outcomes
# Why investigators think it worked THC acts on the endocannabinoid system, a brain signaling network that helps regulate stress responses, mood, memory consolidation, and sleep architecture. REM sleep is the phase when vivid dreaming and emotional-memory processing occur. The trial authors suggest THC may dampen REM-sleep activity that allows traumatic memories to replay with high intensity, reducing the conditions that produce recurrent nightmares.
# How this fits with prior evidence
# Regulatory and clinical context Dronabinol is an established prescription medication in the U.S. and Germany, approved since 1985 for chemotherapy-induced nausea and HIV/AIDS-related anorexia. Using it for PTSD-related nightmares is an off-label application. The trial provides more rigorous clinical evidence but does not by itself establish routine clinical use.
# Practical takeaways for clinicians and patients
# Open questions the study leaves The trial strengthens evidence that THC can reduce nightmare burden, but questions remain about long-term effectiveness, safety over extended use, how benefits compare with other treatments for PTSD nightmares, and which patients are most likely to respond.
A drug made up of THC, the main psychoactive component of cannabis, reduced the severity and incidence of nightmares in people with PTSD
A new approach to treating severe sleep disorders. For many people with post-traumatic stress disorder (PTSD), going to sleep can mean reliving a traumatic experience with frightening intensity. These recurring nightmares can cause severe sleep loss and even create fear of going to bed, while existing medications often
Navy veteran Michael Giardina told Anderson Cooper he was able to "let go" of trauma from his childhood during a psychedelic experience.
As public perception and legislation moves, psychedelic drugs could become accepted treatment for people battling a range of mental health disorders.
Mental health affects every aspect of how we think, feel, and move through […]
Mental health and wellbeing festivals have grown far beyond sitting in a conference […]
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.